In summary, we have identified KPNA2, DTL, BACE2 and DTYMK cfRNAs as potential pan‐tumour liquid biopsy markers for prognostic and therapy monitoring in melanoma independent of the mutational genotype. The gene discussed is DTL; the disease is melanoma.